Trial Profile
Randomized, Open, Multi-Center, Phase III Study to Evaluate Efficacy and Safety in Chemotherapy-induced Neutropenia of Once-per-cycle DA-3031(PEG-G-CSF) and Daily G-CSF in Patients With Malignancies Receiving Myelosuppressive Chemotherapy
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Pegfilgrastim (Primary) ; Filgrastim
- Indications Neutropenia
- Focus Therapeutic Use
- Sponsors Dong-A ST
- 14 May 2014 New trial record